27 August 2019 - Mayne Pharma Group is pleased to announce the PBS has approved the reimbursement of Kapanol low dose sustained-release 10 mg and 20 mg morphine capsules for the treatment of chronic breathlessness in palliative care patients with advanced disease.
From 1 September 2019, the use of Kapanol for chronic breathlessness will be a new indication on the PBS Palliative Care Schedule.
This is an addition to Kapanol’s current PBS General Schedule listing for use in chronic severe disabling pain unresponsive to non-opioid analgesics.